ArticleAmerican journal of preventive cardiology2021
COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVD.
Article in American journal of preventive cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Risk factors for long-term cardiovascular post-acute sequelae of COVID-19 infection: A nested case-control study in Hong Kong.NPJ cardiovascular health · 2024Article
- International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.Nature reviews. Cardiology · 2023Review
- SARS-CoV-2 reinfection: Adding insult to dysfunctional endothelium in patients with atherosclerotic cardiovascular disease.Atherosclerosis plus · 2023Review
- Contemporary Homozygous Familial Hypercholesterolemia in the United States: Insights From the CASCADE FH Registry.Journal of the American Heart Association · 2023Article
- Benefits and Harms of COVID-19 Vaccines in Cardiovascular Disease: A Comprehensive Review.Journal of lipid and atherosclerosis · 2023Review
- Familial Hypercholesterolemia Patients with COVID-19-Effective Cholesterol-Lowering Therapy is Urgent both during and after Infection.Reviews in cardiovascular medicine · 2022Review
- COVID-19 and Cardiometabolic Health: Lessons Gleaned from the Pandemic and Insights for the Next Wave.Current atherosclerosis reports · 2022Review
- Minimally invasive treatment of left main coronary artery thrombosis in a young patient with COVID-19.BMJ case reports · 2022Article
- Cholesterol-lowering drugs for high-risk hypercholesterolemia patients with COVID-19 while on Paxlovid™ therapy.Future virology · 2022Review
- Prevention of Cardiovascular Burden in COVID-19 Patients Suffering from Familial Hypercholesterolemia: A Global Challenge.Cardiology and therapy · 2022Article
- Editorial: Genetics of familial hypercholesterolemia: New insight-Volume II.Frontiers in genetics · 2022Article
- Long-Term Cardiovascular and Cerebrovascular Challenges Posed by COVID-19 in Patients With Familial Hypercholesterolemia.Frontiers in pharmacology · 2022Article
- Patients with familial hypercholesterolemia and COVID-19: Efficient and ongoing cholesterol lowering is paramount for the prevention of acute myocardial infarction.American journal of preventive cardiology · 2021Article
- Familial hypercholesterolemia and COVID-19: A menacing but treatable vasculopathic condition.Atherosclerosis plus · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.